文献速递前列腺癌

咖啡摄入、咖啡因代谢基因型与前列腺癌男性生存

Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2022-08-20

基于PRACTICAL联盟七项研究5727例前列腺癌男性数据,评估咖啡摄入与咖啡因代谢基因型对总生存和前列腺癌特异性生存的影响。高咖啡摄入与临床局限期患者及CYP1A2 AA基因型者前列腺癌特异性生存延长相关,但总体关联未达统计学显著。

要点

  • 高咖啡摄入与前列腺癌特异性生存延长相关,但总体未达统计学显著(HR 0.85,95%CI 0.68-1.08)。
  • 临床局限期患者中,高咖啡摄入与前列腺癌特异性生存延长相关(HR 0.66,95%CI 0.44-0.98,p=0.040)。
  • CYP1A2 AA基因型者中,高咖啡摄入与前列腺癌特异性生存延长相关(HR 0.67,95%CI 0.49-0.93,p=0.017),与AC/CC基因型存在交互作用(p=0.042)。

核心结论

  • 咖啡摄入与CYP1A2 -163AA(*1F/*1F)基因型男性的前列腺癌特异性生存延长相关,该发现需进一步重复验证。

研究设计与样本

  • 基于PRACTICAL联盟数据库,纳入来自七项美国、澳大利亚和欧洲研究的5727例前列腺癌男性,均有CYP1A2 -163C>A rs762551单核苷酸变异数据、咖啡摄入数据及超过6个月随访。

主要发现

  • 高咖啡摄入与较长的前列腺癌特异性生存(HR 0.85,95%CI 0.68-1.08;p=0.18)和总生存(HR 0.90,95%CI 0.77-1.07;p=0.24)相关,但未达统计学显著。
  • 临床局限期患者中,高咖啡摄入与较长的前列腺癌特异性生存相关(HR 0.66,95%CI 0.44-0.98;p=0.040),晚期患者结果相似(HR 0.92,95%CI 0.69-1.23;p=0.6)。
  • CYP1A2 AA基因型男性中,高咖啡摄入与较长的前列腺癌特异性生存相关(HR 0.67,95%CI 0.49-0.93;p=0.017),AC/CC基因型中无此关联(p=0.8),交互作用检验p=0.042。
  • 亚组分析中未观察到咖啡摄入与总生存的关联(p>0.05)。

局限性

  • 名义统计学显著性。
  • 残余混杂。
  • 该发现需进一步重复验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coffee intake may lower prostate cancer risk and progression, but postdiagnosis outcomes by caffeine metabolism genotype are not well characterized. OBJECTIVE: To evaluate associations between coffee intake, caffeine metabolism genotype, and survival in a large, multicenter study of men with prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Data from The PRACTICAL Consortium database for 5727 men with prostate cancer from seven US, Australian, and European studies were included. The cases included had data available for the CYP1A2 -163C>A rs762551 single-nucleotide variant associated with caffeine metabolism, coffee intake, and >6 mo of follow-up. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable-adjusted Cox proportional hazards models across pooled patient-level data were used to compare the effect of coffee intake (categorized as low [reference], high, or none/very low) in relation to overall survival (OS) and prostate cancer-specific survival (PCSS), with stratified analyses conducted by clinical disease risk and genotype. RESULTS AND LIMITATIONS: High coffee intake appeared to be associated with longer PCSS (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.68-1.08; p = 0.18) and OS (HR 0.90, 95% CI 0.77-1.07; p = 0.24), although results were not statistically significant. In the group with clinically localized disease, high coffee intake was associated with longer PCSS (HR 0.66, 95% CI 0.44-0.98; p = 0.040), with comparable results for the group with advanced disease (HR 0.92, 95% CI 0.69-1.23; p = 0.6). High coffee intake was associated with longer PCSS among men with the CYP1A2 AA (HR 0.67, 95% CI 0.49-0.93; p = 0.017) but not the AC/CC genotype (p = 0.8); an interaction was detected (p = 0.042). No associations with OS were observed in subgroup analyses (p > 0.05). Limitations include the nominal statistical significance and residual confounding. CONCLUSIONS: Coffee intake was associated with longer PCSS among men with a CYP1A2 -163AA (*1F/*1F) genotype, a finding that will require further replication. PATIENT SUMMARY: It is likely that coffee intake is associated with longer prostate cancer-specific survival in certain groups, but more research is needed to fully understand which men may benefit and why.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gregg JR, Kim J, Logothetis C, et al. Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer. Eur Urol Oncol. 2022. PMID: 35995710. doi:10.1016/j.euo.2022.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。